How Rescheduling Hydrocodone Combination Products Will Reduce Abuse

Published Online: Wednesday, January 22, 2014
Follow Pharmacy_Times:
In this video, Mary Lynn McPherson, PharmD, professor and vice chair at the University of Maryland School of Pharmacy, explains how rescheduling hydrocodone combination products as Schedule II drugs will help reduce levels of abuse.
 
This is the seventh in a series of videos in which Dr. McPherson argues in favor of categorizing hydrocodone combination products as Schedule II drugs, and Jeff Fudin, PharmD, argues against doing so. (Drs. McPherson and Fudin were assigned to take these positions for a session at the American Society of Health-System Pharmacists 2013 Midyear Clinical Meeting in Orlando, and their arguments do not necessarily reflect their personal positions on the issue.)
 
These videos were filmed at the ASHP 2013 Midyear Clinical Meeting in Orlando.

Related Articles
Updated REMS attempts to stem the flow of extended-release, long-acting opioids to addicts while ensuring patients in severe pain retain access.
A University of Kentucky pharmacy professor has developed a nasal spray of naloxone (Narcan) to treat potentially fatal overdoses from heroin and prescription opioids.
Drugs that contain hydrocodone will be moved to a more restrictive category of the Controlled Substances Act.
Latest Issues
$auto_registration$